Hospital
Kaleida Health
Kaleida Health was paid $80.65M by Medicaid between Jan 2018 and Dec 2024, across 405 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoKALEIDA HEALTH
BUFFALO, NY 14203
BUFFALO, NY 14203
33aNPI1245365196assigned 02/22/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$80.65M
24GClaims961,840
24DCodes billed405
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#18 of 231
Median peer was paid$561K
This provider vs. median144×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,194 | $235K | |
| 2019 | 46,001 | $3.26M | |
| 2020 | 62,933 | $4.58M | |
| 2021 | 161,395 | $11.98M | |
| 2022 | 220,714 | $16.98M | |
| 2023 | 259,618 | $22.28M | |
| 2024incomplete | 205,985 | $21.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 57,271 | 54,501 | $12.38M |
| G0378 | Hospital observation service, per hour | 9.7% | 5,321 | 5,226 | $7.80M |
| 41899 | Unlisted procedure, dentoalveolar structures | 8.0% | 5,357 | 4,813 | $6.46M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.7% | 56,342 | 50,048 | $6.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.1% | 26,792 | 25,904 | $5.70M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 3.3% | 2,009 | 1,996 | $2.64M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.9% | 1,704 | 1,704 | $2.31M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.4% | 15,689 | 14,501 | $1.91M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 8,385 | 8,247 | $1.58M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.9% | 12,210 | 10,637 | $1.55M |
| 87631 | 1.9% | 30,662 | 29,181 | $1.55M | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.5% | 8,777 | 8,384 | $1.17M |
393 more codes
| 59025 | Fetal non-stress test | 1.4% | 9,752 | $1.16M |
| 99203 | Doctor's office visit, new patient (routine) | 1.4% | 8,465 | $1.15M |
| 90834 | Psychotherapy session, about 45 minutes | 1.4% | 8,777 | $1.09M |
| 42830 | 1.2% | 808 | $978K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 1,044 | $802K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 21,642 | $759K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,382 | $749K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 4,057 | $720K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,907 | $720K |
| 99285 | Emergency room visit (most serious) | <1% | 5,426 | $652K |
| 54161 | <1% | 609 | $633K | |
| 93975 | <1% | 1,662 | $616K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,613 | $596K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,774 | $572K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 416 | $539K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,888 | $538K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 21,334 | $524K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 6,499 | $522K |
| 96415 | <1% | 983 | $502K | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 169 | $485K |
| 76770 | <1% | 2,280 | $464K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 698 | $449K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 21,658 | $445K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 7,058 | $436K |
| 80053 | Comprehensive metabolic panel | <1% | 18,085 | $418K |
| 96112 | <1% | 2,913 | $413K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,501 | $390K |
| 99205 | Prolong outpt/office vis | <1% | 2,853 | $387K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,789 | $386K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,026 | $367K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,449 | $354K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 3,063 | $318K |
| 12011 | <1% | 718 | $295K | |
| 95819 | <1% | 1,809 | $278K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,606 | $266K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,634 | $248K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 9,721 | $232K |
| 87481 | <1% | 3,997 | $210K | |
| 51600 | <1% | 368 | $203K | |
| 86900 | <1% | 5,857 | $201K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,151 | $197K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,046 | $181K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,990 | $178K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,400 | $175K |
| 76801 | <1% | 2,444 | $173K | |
| 12001 | <1% | 426 | $172K | |
| 76818 | <1% | 2,072 | $170K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,574 | $166K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,467 | $165K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 454 | $164K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,403 | $163K |
| 76000 | <1% | 1,056 | $161K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,355 | $149K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 2,069 | $147K |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,861 | $146K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,820 | $146K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,350 | $140K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 782 | $136K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 3,495 | $135K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 557 | $130K |
| 83655 | <1% | 8,786 | $125K | |
| 92567 | <1% | 3,433 | $120K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 935 | $115K |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 599 | $111K |
| 76813 | <1% | 1,514 | $109K | |
| 76820 | <1% | 2,501 | $107K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,129 | $106K |
| 76821 | <1% | 2,021 | $98K | |
| 86901 | <1% | 5,826 | $97K | |
| 86850 | <1% | 5,771 | $94K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 654 | $93K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,166 | $91K |
| 96113 | <1% | 866 | $86K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,668 | $83K |
| 74455 | <1% | 367 | $83K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,153 | $82K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,692 | $79K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 552 | $73K |
| 86003 | <1% | 1,055 | $73K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,271 | $72K |
| 67311 | <1% | 26 | $70K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,084 | $69K |
| 97161 | <1% | 694 | $68K | |
| D2390 | <1% | 266 | $65K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 7,192 | $65K |
| 41010 | <1% | 128 | $64K | |
| 99385 | <1% | 460 | $63K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 546 | $63K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,152 | $62K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 544 | $55K |
| 81025 | <1% | 14,267 | $55K | |
| 85027 | <1% | 10,110 | $55K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,603 | $54K |
| 81002 | <1% | 27,218 | $53K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,162 | $52K |
| 92552 | <1% | 986 | $49K | |
| 86780 | <1% | 6,964 | $46K | |
| 92610 | <1% | 374 | $46K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,634 | $46K |
| 74018 | <1% | 7,864 | $45K | |
| 92555 | <1% | 1,324 | $45K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,277 | $43K |
| 76830 | Ultrasound, transvaginal | <1% | 752 | $41K |
| 90715 | <1% | 1,219 | $40K | |
| 90686 | <1% | 2,932 | $39K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 589 | $39K |
| D2330 | <1% | 240 | $38K | |
| 93976 | <1% | 109 | $38K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 879 | $38K |
| 80061 | Lipid panel | <1% | 3,354 | $37K |
| 96910 | <1% | 628 | $37K | |
| 96900 | <1% | 1,228 | $36K | |
| 97113 | <1% | 585 | $35K | |
| 92579 | <1% | 634 | $34K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 168 | $33K |
| 94010 | <1% | 1,700 | $31K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 36 | $30K |
| 25605 | <1% | 68 | $30K | |
| 97802 | <1% | 1,326 | $29K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 183 | $29K |
| 86803 | <1% | 4,789 | $29K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,902 | $28K |
| 70486 | <1% | 205 | $28K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 150 | $28K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 80 | $27K |
| 84439 | <1% | 3,041 | $27K | |
| 82803 | <1% | 1,118 | $26K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 140 | $26K |
| 92588 | <1% | 317 | $24K | |
| 90670 | <1% | 544 | $24K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,206 | $23K |
| 43762 | <1% | 132 | $23K | |
| D0120 | Dental checkup, returning patient | <1% | 442 | $22K |
| 94060 | <1% | 733 | $22K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,089 | $22K |
| 86141 | <1% | 4,862 | $21K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 924 | $21K |
| 87070 | <1% | 9,526 | $20K | |
| 87340 | <1% | 4,296 | $20K | |
| 76800 | <1% | 341 | $20K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 148 | $20K |
| 81513 | <1% | 3,428 | $19K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 134 | $18K |
| 41520 | <1% | 12 | $18K | |
| 97803 | <1% | 753 | $18K | |
| 76885 | <1% | 507 | $15K | |
| 99386 | <1% | 118 | $15K | |
| 86762 | <1% | 2,445 | $15K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 76 | $15K |
| 83516 | <1% | 555 | $15K | |
| C1886 | Catheter, extravascular tissue ablation, any modality (insertable) | <1% | 343 | $15K |
| 76377 | <1% | 1,853 | $15K | |
| 84702 | <1% | 1,894 | $14K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,612 | $14K |
| 82784 | <1% | 1,229 | $13K | |
| 82785 | <1% | 854 | $13K | |
| 74019 | <1% | 3,465 | $13K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 126 | $12K |
| 72141 | <1% | 41 | $12K | |
| 76870 | <1% | 359 | $11K | |
| 84403 | <1% | 556 | $11K | |
| 86317 | <1% | 276 | $11K | |
| 90671 | <1% | 195 | $11K | |
| 12002 | <1% | 26 | $10K | |
| 29125 | <1% | 54 | $10K | |
| D1351 | Sealant - per tooth | <1% | 116 | $10K |
| 76536 | <1% | 380 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,755 | $9K |
| 86787 | <1% | 2,089 | $9K | |
| 87480 | <1% | 722 | $9K | |
| 87510 | <1% | 718 | $9K | |
| 82105 | <1% | 1,262 | $9K | |
| 99443 | <1% | 72 | $9K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,984 | $9K |
| 92652 | <1% | 150 | $8K | |
| 73070 | <1% | 1,619 | $8K | |
| 90680 | <1% | 278 | $8K | |
| 83735 | <1% | 2,260 | $8K | |
| 82728 | <1% | 1,006 | $8K | |
| 72170 | <1% | 1,418 | $8K | |
| 83020 | <1% | 1,092 | $8K | |
| 84146 | <1% | 538 | $8K | |
| 90651 | <1% | 145 | $7K | |
| 99441 | <1% | 105 | $7K | |
| 97162 | <1% | 63 | $7K | |
| 85018 | <1% | 1,930 | $7K | |
| 87147 | <1% | 2,668 | $7K | |
| 90633 | <1% | 251 | $7K | |
| 86480 | <1% | 95 | $7K | |
| 87660 | <1% | 865 | $7K | |
| 82570 | <1% | 2,095 | $7K | |
| 73610 | <1% | 1,524 | $6K | |
| 81001 | <1% | 8,189 | $6K | |
| 73090 | <1% | 1,580 | $6K | |
| 16020 | <1% | 21 | $6K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 136 | $6K |
| 88304 | <1% | 594 | $6K | |
| 77072 | <1% | 482 | $6K | |
| 73100 | <1% | 996 | $6K | |
| 84100 | <1% | 2,498 | $6K | |
| 87077 | <1% | 1,917 | $6K | |
| 87186 | <1% | 2,236 | $6K | |
| 80197 | <1% | 569 | $6K | |
| 98968 | <1% | 156 | $6K | |
| 82948 | <1% | 3,289 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,363 | $6K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,659 | $6K |
| 87088 | <1% | 2,162 | $5K | |
| 99442 | <1% | 96 | $5K | |
| 83001 | <1% | 395 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,193 | $5K |
| 90734 | <1% | 162 | $5K | |
| 73630 | <1% | 1,243 | $5K | |
| 85651 | <1% | 3,258 | $5K | |
| 83970 | <1% | 129 | $5K | |
| 98967 | <1% | 215 | $5K | |
| 69210 | <1% | 73 | $5K | |
| 73590 | <1% | 1,035 | $4K | |
| 82607 | <1% | 406 | $4K | |
| 36416 | <1% | 171 | $4K | |
| 85032 | <1% | 3,320 | $4K | |
| 84156 | <1% | 1,979 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 167 | $4K |
| 85610 | <1% | 1,773 | $4K | |
| 86710 | <1% | 1,701 | $4K | |
| 72082 | <1% | 589 | $4K | |
| 90672 | <1% | 262 | $3K | |
| 83540 | <1% | 907 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,506 | $3K |
| 83002 | <1% | 229 | $3K | |
| 70491 | <1% | 12 | $3K | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | <1% | 266 | $3K |
| 85730 | <1% | 1,224 | $3K | |
| 84436 | <1% | 675 | $3K | |
| 92002 | <1% | 33 | $3K | |
| 10060 | <1% | 12 | $3K | |
| 96376 | <1% | 780 | $3K | |
| 73560 | <1% | 873 | $3K | |
| 85008 | <1% | 498 | $3K | |
| 83550 | <1% | 698 | $3K | |
| 72146 | <1% | 25 | $3K | |
| 88342 | <1% | 39 | $3K | |
| 73110 | <1% | 385 | $3K | |
| 82746 | <1% | 238 | $3K | |
| 82670 | <1% | 112 | $2K | |
| 73130 | <1% | 919 | $2K | |
| 82627 | <1% | 148 | $2K | |
| 0001A | <1% | 79 | $2K | |
| 90480 | <1% | 43 | $2K | |
| 90647 | <1% | 120 | $2K | |
| 74240 | <1% | 52 | $2K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 12 | $2K |
| 92523 | <1% | 13 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 29 | $2K |
| 80076 | <1% | 210 | $2K | |
| 83615 | <1% | 1,281 | $2K | |
| 94761 | <1% | 672 | $2K | |
| D1120 | Dental cleaning, child | <1% | 41 | $2K |
| 92553 | <1% | 32 | $2K | |
| 83690 | <1% | 1,867 | $2K | |
| 81003 | <1% | 5,657 | $2K | |
| 82330 | <1% | 352 | $2K | |
| 88300 | <1% | 967 | $2K | |
| C9399 | Unclassified drugs or biologicals | <1% | 686 | $2K |
| 84132 | <1% | 590 | $2K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 12 | $2K |
| 98966 | <1% | 142 | $2K | |
| 85014 | <1% | 655 | $2K | |
| 76882 | <1% | 41 | $2K | |
| 94664 | <1% | 477 | $2K | |
| 70360 | <1% | 395 | $2K | |
| 90688 | <1% | 182 | $2K | |
| 90678 | <1% | 50 | $2K | |
| 90658 | <1% | 230 | $2K | |
| 77073 | <1% | 193 | $2K | |
| 90723 | <1% | 123 | $1K | |
| 86256 | <1% | 81 | $1K | |
| 73000 | <1% | 264 | $1K | |
| 0002A | <1% | 36 | $1K | |
| 84480 | <1% | 165 | $1K | |
| 90656 | <1% | 652 | $1K | |
| 99422 | <1% | 43 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 72 | $1K |
| 82677 | <1% | 98 | $1K | |
| 72040 | <1% | 347 | $1K | |
| 73140 | <1% | 222 | $987.71 | |
| 87210 | <1% | 758 | $976.79 | |
| 86376 | <1% | 89 | $914.10 | |
| 82040 | <1% | 185 | $900.33 | |
| 74430 | <1% | 25 | $858.84 | |
| 82150 | <1% | 493 | $850.55 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 66 | $836.07 |
| 99423 | <1% | 26 | $828.62 | |
| 84402 | <1% | 54 | $802.60 | |
| 86592 | <1% | 249 | $774.24 | |
| 90697 | <1% | 207 | $770.79 | |
| 80329 | <1% | 87 | $756.48 | |
| 87529 | <1% | 26 | $743.62 | |
| 94760 | <1% | 1,286 | $699.71 | |
| 86696 | <1% | 66 | $681.20 | |
| 86706 | <1% | 94 | $676.51 | |
| 82043 | <1% | 113 | $671.81 | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 14 | $652.26 |
| J3490 | Unclassified drugs | <1% | 14 | $648.19 |
| 82977 | <1% | 165 | $624.36 | |
| 59430 | <1% | 443 | $619.90 | |
| 82533 | <1% | 43 | $597.13 | |
| 86336 | <1% | 114 | $571.81 | |
| 0072A | <1% | 15 | $561.60 | |
| 87400 | <1% | 3,468 | $558.98 | |
| 86800 | <1% | 62 | $548.86 | |
| 90710 | <1% | 27 | $542.30 | |
| 87420 | <1% | 1,501 | $536.77 | |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $523.59 |
| 85045 | <1% | 441 | $518.85 | |
| C1769 | Guide wire | <1% | 38 | $499.96 |
| 84703 | <1% | 273 | $496.99 | |
| 87040 | <1% | 1,423 | $491.45 | |
| 87101 | <1% | 111 | $470.50 | |
| 84145 | <1% | 204 | $456.66 | |
| 90716 | <1% | 12 | $449.23 | |
| 0071A | <1% | 12 | $448.00 | |
| 82550 | <1% | 273 | $446.40 | |
| 86708 | <1% | 61 | $421.21 | |
| 86709 | <1% | 60 | $384.49 | |
| 74230 | <1% | 13 | $366.07 | |
| 82947 | <1% | 572 | $357.35 | |
| 73552 | <1% | 156 | $352.23 | |
| 82951 | <1% | 28 | $327.23 | |
| 90707 | <1% | 14 | $325.02 | |
| 88312 | <1% | 82 | $317.63 | |
| 84550 | <1% | 154 | $308.70 | |
| 88313 | <1% | 15 | $289.04 | |
| 72081 | <1% | 51 | $279.05 | |
| 83498 | <1% | 15 | $278.50 | |
| 84305 | <1% | 12 | $263.31 | |
| 73564 | <1% | 30 | $247.08 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,024 | $242.19 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 12 | $229.00 |
| 85246 | <1% | 12 | $219.49 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,001 | $208.51 |
| 83525 | <1% | 28 | $205.21 | |
| 73060 | <1% | 58 | $192.91 | |
| 86769 | <1% | 12 | $190.25 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,073 | $187.98 |
| 90700 | <1% | 12 | $166.63 | |
| 99417 | Prolong home eval add 15m | <1% | 822 | $154.94 |
| 86038 | <1% | 36 | $153.16 | |
| 86704 | <1% | 17 | $150.44 | |
| 86695 | <1% | 15 | $137.35 | |
| 83605 | <1% | 129 | $110.12 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 12 | $109.60 |
| 84484 | <1% | 52 | $106.73 | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,785 | $106.70 |
| 82248 | <1% | 43 | $104.09 | |
| 86160 | <1% | 13 | $102.99 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,876 | $101.96 |
| 73030 | <1% | 69 | $101.78 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,800 | $100.60 |
| 82010 | <1% | 118 | $99.84 | |
| 84295 | <1% | 389 | $93.41 | |
| 82952 | <1% | 25 | $83.71 | |
| 86644 | <1% | 38 | $80.34 | |
| 86645 | <1% | 37 | $62.09 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 361 | $59.34 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 447 | $56.96 |
| 86308 | <1% | 136 | $53.94 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,324 | $53.56 |
| 84460 | <1% | 13 | $51.21 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,235 | $49.71 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 762 | $48.95 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,545 | $48.65 |
| 82247 | <1% | 15 | $36.74 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,578 | $30.05 |
| 87184 | <1% | 15 | $19.92 | |
| 86665 | <1% | 13 | $19.30 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,375 | $16.95 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 31 | $15.96 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 250 | $10.87 |
| 83935 | <1% | 15 | $6.16 | |
| 80320 | <1% | 53 | $5.45 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 812 | $1.58 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 39 | $1.40 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 215 | $0.37 |
| 99358 | Prolong nursin fac eval 15m | 0% | 90 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 211 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 23 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 13 | $0.00 |
| 92015 | Determination of refractive state | 0% | 15 | $0.00 |
| 91321 | 0% | 35 | $0.00 | |
| 85384 | 0% | 12 | $0.00 | |
| 74022 | 0% | 14 | $0.00 | |
| 82435 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCROREY, ANGELA (AR MANAGER)
Parent organizationKALEIDA HEALTH
| Provider | Location | Paid |
|---|---|---|
| Kaleida Health | Buffalo, NY | $30.80M |
| Kaleida Health | Williamsville, NY | $11.67M |
| Kaleida Health | North Tonawanda, NY | $5.40M |
| Kaleida Health | Buffalo, NY | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.